Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in child...
|Journal Title:||Journal of Clinical Oncology Vol. 26; no. 7; pp. 1106 - 1111|
|Authors:||Eric Larsen, Elly Barry, Lynda Vrooman, Suzanne Dahlberg, Donna Neuberg, Barbara Asselin, Uma Athale, Luis Clavell, Albert Moghrabi, Yvan Samson, Marshall Schorin, Harvey Cohen, Steven Lipshultz, Stephen Sallan, Lewis Silverman|
|Published:||March 1, 2008|